These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8210835)

  • 1. Biological markers of prognosis in transitional cell carcinoma of the bladder: current concepts.
    Aprikian AG; Sarkis AS; Reuter VE; Cordon-Cardo C; Sheinfeld J
    Semin Urol; 1993 Aug; 11(3):137-44. PubMed ID: 8210835
    [No Abstract]   [Full Text] [Related]  

  • 2. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical appraisal of tumor markers in bladder cancer.
    Fradet Y; Cordon-Cardo C
    Semin Urol; 1993 Aug; 11(3):145-53. PubMed ID: 8105526
    [No Abstract]   [Full Text] [Related]  

  • 4. p53 and bladder cancer.
    Xing X
    N Engl J Med; 1995 Apr; 332(14):957-8. PubMed ID: 7877657
    [No Abstract]   [Full Text] [Related]  

  • 5. p53 and bladder cancer.
    Wood LL
    N Engl J Med; 1995 Apr; 332(14):958. PubMed ID: 7877658
    [No Abstract]   [Full Text] [Related]  

  • 6. p53 and bladder cancer.
    Li WW; Li VW; Tsakayannis D
    N Engl J Med; 1995 Apr; 332(14):957; author reply 958. PubMed ID: 7794332
    [No Abstract]   [Full Text] [Related]  

  • 7. Markers of prognosis in superficial bladder cancer.
    Fradet Y
    Semin Urol; 1992 Feb; 10(1):28-38. PubMed ID: 1565901
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature?
    Cordon-Cardo C
    J Clin Oncol; 2004 Mar; 22(6):975-7. PubMed ID: 14981108
    [No Abstract]   [Full Text] [Related]  

  • 10. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
    Bian W; Xu Z
    Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
    Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
    BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent diagnostic modalities for bladder cancer.
    Sheinfeld J; Cordon-Cardo C; Bander NH
    Immunol Ser; 1990; 53():485-97. PubMed ID: 2151621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic factors and markers used in urothelial carcinoma of the bladder].
    Billerey C; Vieillefond A
    Ann Pathol; 1999; 19(5 Suppl):S107-9. PubMed ID: 10599469
    [No Abstract]   [Full Text] [Related]  

  • 15. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.
    Furihata M; Inoue K; Ohtsuki Y; Hashimoto H; Terao N; Fujita Y
    Cancer Res; 1993 Oct; 53(20):4823-7. PubMed ID: 8402668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].
    Leng J; Zhang Y; Yao X; Wen K
    Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic markers as promising prognosticators for bladder cancer.
    Kim YK; Kim WJ
    Int J Urol; 2009 Jan; 16(1):17-22. PubMed ID: 18721202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of p53 oncoprotein immunohistochemistry in the follow-up of bladder carcinoma: a 5-year study].
    Moreno Sierra J; López García Asenjo JA; Redondo González E; Fernández Pérez C; Maestro de las Casas ML; Blanco Jiménez E; Silmi Moyano A; Resel Estévez L
    Arch Esp Urol; 1999 Oct; 52(8):840-8. PubMed ID: 10589115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.